LEADS BIOLABS-B (09887) rose more than 5%, with a gain of 4.94% at the time of writing to HK$55.2, and a turnover of HK$18.0035 million. On January 22, LEADS BIOLABS-B announced that on January 22, 2026, the European Commission (EC) issued an executive decision dated January 9, 2026, granting orphan drug designation to the PD-L1/4-1BB bispecific antibody VELIXENT™ (Opatisumimab, LBL-024) for the treatment of extra-pulmonary neuroendocrine carcinoma. This marks the second orphan drug designation for VELIXENT™, following its prior designation by the U.S. Food and Drug Administration (FDA), representing another significant milestone in the global development progress of VELIXENT™.